Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response)

NCT03643133 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03643133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03643133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response)
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 23, 2018
Completion date
October 31, 2033
Enrollment
60 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma